RXRX · Recursion Pharmaceuticals, Inc.
$3.20
+1.27% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-3.5
Dividend yield
—
Beta
1.07
Avg volume
19M
Employees
1K
Daily Change %
1.27%
5 Days Change
-11.43%
10 Days Change
-5.44%
30 Days Change
-4.03%
60 Days Change
-9.69%
Month to Day Change
-3.45%
Year to Day Change
-21.39%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RXRX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-14
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$5.50
+74.1% vs priceJP Morgan
Overweight$10.00
+216.5% vs priceBank of America
Neutral$6.00
+89.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-14 | Morgan Stanley | Maintains | Equal-Weight | $5.00 → $5.50 |
| 2026-05-07 | Needham | Reiterates | Buy | $8.00 |
| 2026-04-30 | JP Morgan | Maintains | Overweight | $11.00 → $10.00 |
| 2026-02-26 | Bank of America | Maintains | Neutral | $7.00 → $6.00 |
| 2026-02-26 | Needham | Reiterates | Buy | $8.00 |
| 2025-12-17 | JP Morgan | Upgrade | Neutral → Overweight | $10.00 → $11.00 |
| 2025-09-11 | Needham | Reiterates | Buy | $8.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 3.0% below the 50-day MA ($3.30).
- Price vs 200-day MA: Trading 11.8% below the 200-day MA ($3.63).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.03) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($2.84) and high ($6.79).
RXRX Price Chart
Loading chart for RXRX…
Fundamentals
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.